Table 2.

Multivariate models

EffectPpCR ORaPFS HRb95% CIcArm
Model A
 Treatment arm0.240.640.33–1.24L v T
2.091.08–4.03L+T v T
 Hormone receptor negative0.00082.491.46–4.25
 Tumor size0.241.390.80–2.41
 Lymph node status0.450.770.38–1.56
 Conservative plan0.510.820.45–1.47
 Log2(p95HER2) by Arm0.080.970.69–1.37L
1.671.06–2.64T
1.601.11–2.31L+T
 Log2(p95HER2)0.006
Model B
 Treatment arm0.280.840.45–1.55L v T
2.891.54–5.44L+T v T
 Hormone receptor negative0.0032.181.30–3.66
 Tumor size0.461.220.72–2.06
 Lymph node status0.580.820.41–1.66
 Conservative plan0.530.830.47–1.47
 Log2(HER2) by Arm0.061.300.97–1.75L
1.210.93–1.57T
2.021.42–2.87L+T
 Log2(HER2)<0.001
Model C
 Treatment arm0.261.200.68–2.12L v T
0.720.38–1.35L+T v T
 Hormone receptor negative0.011.911.15–3.18
 Tumor size0.0490.620.38–1.00
 Lymph node status0.290.720.39–1.32
 Conservative plan0.100.600.33–1.10
 Log2(p95HER2)0.010.71d0.54–0.93
Model D
 Treatment arm0.121.350.79–2.29L v T
0.740.41–1.34L+T v T
 Hormone receptor negative0.051.601.00–2.56
 Tumor size0.130.700.44–1.11
 Lymph node status0.240.700.39–1.27
 Conservative plan0.040.550.31–0.97
 Log2(HER2)0.010.67d0.50–0.91
  • aOR for logistic regression model relating pCR to clinicopathologic variables in models A and B.

  • bHR for Cox model analysis relating PFS to clinicopathologic variables in models C and D.

  • c95% confidence interval.

  • dHR of the interquartile range in p95HER2 or HER2.